The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
1-hydroxy-1-norresistomycin results in increased expression of CASP3 mRNA; 1-hydroxy-1-norresistomycin results in increased expression of CASP3 protein
1-hydroxy-1-norresistomycin results in increased expression of CASP9 mRNA; 1-hydroxy-1-norresistomycin results in increased expression of CASP9 protein
1-hydroxy-1-norresistomycin results in increased expression of CDKN1A mRNA; 1-hydroxy-1-norresistomycin results in increased expression of CDKN1A protein
1-methylphenanthrene results in increased activity of AHR protein [1-methylphenanthrene results in increased activity of AHR protein] which results in increased expression of CYP1A1 mRNA
1-methylphenanthrene results in increased expression of CYP1A1 protein 1-methylphenanthrene affects the expression of CYP1A1 mRNA 1-methylphenanthrene affects the reaction [Benzo(a)pyrene affects the expression of CYP1A1 mRNA]; [1-methylphenanthrene results in increased activity of AHR protein] which results in increased expression of CYP1A1 mRNA [Benzo(a)pyrene co-treated with 1-methylphenanthrene] affects the expression of CYP1A1 mRNA
1-methylphenanthrene affects the expression of CYP1B1 mRNA 1-methylphenanthrene affects the reaction [Benzo(a)pyrene affects the expression of CYP1B1 mRNA]
[AKR1C1 protein results in increased reduction of 3-nitrobenzanthrone] which results in increased chemical synthesis of 3-aminobenzanthrone; [AKR1C1 protein results in increased reduction of 3-nitrobenzanthrone] which results in increased chemical synthesis of N-hydroxy-3-aminobenzanthrone
[AKR1C2 protein results in increased reduction of 3-nitrobenzanthrone] which results in increased chemical synthesis of 3-aminobenzanthrone; [AKR1C2 protein results in increased reduction of 3-nitrobenzanthrone] which results in increased chemical synthesis of N-hydroxy-3-aminobenzanthrone
AKR1C3 protein results in increased reduction of 3-nitrobenzanthrone [AKR1C3 protein results in increased reduction of 3-nitrobenzanthrone] which results in increased chemical synthesis of 3-aminobenzanthrone; [AKR1C3 protein results in increased reduction of 3-nitrobenzanthrone] which results in increased chemical synthesis of N-hydroxy-3-aminobenzanthrone
3-nitrobenzanthrone results in increased expression of and results in increased phosphorylation of AKT1 protein; EREG protein affects the reaction [3-nitrobenzanthrone results in increased phosphorylation of AKT1 protein]
CYP1A1 protein affects the reaction [3-nitrobenzanthrone results in increased abundance of Reactive Oxygen Species] 3-nitrobenzanthrone results in increased expression of CYP1A1 mRNA
3-nitrobenzanthrone results in increased expression of EREG mRNA; 3-nitrobenzanthrone results in increased expression of EREG protein EREG protein affects the reaction [3-nitrobenzanthrone results in increased expression of SOX9 protein]; EREG protein affects the reaction [3-nitrobenzanthrone results in increased expression of TWIST2 protein]; EREG protein affects the reaction [3-nitrobenzanthrone results in increased phosphorylation of AKT1 protein]; EREG protein affects the reaction [3-nitrobenzanthrone results in increased phosphorylation of MAPK1 protein]; EREG protein affects the reaction [3-nitrobenzanthrone results in increased phosphorylation of MAPK3 protein]; EREG protein affects the reaction [3-nitrobenzanthrone results in increased phosphorylation of STAT3 protein]
[NAT2 protein co-treated with 3-nitrobenzanthrone] results in increased mutagenesis of HPRT1 gene; [SULT1A1 protein co-treated with 3-nitrobenzanthrone] results in increased mutagenesis of HPRT1 gene
3-nitrobenzanthrone results in increased expression of IL6 mRNA 3-nitrobenzanthrone results in increased secretion of IL6 protein IL6 protein affects the reaction [3-nitrobenzanthrone results in increased phosphorylation of MAPK1 protein]; IL6 protein affects the reaction [3-nitrobenzanthrone results in increased phosphorylation of MAPK3 protein]; IL6 protein affects the reaction [3-nitrobenzanthrone results in increased phosphorylation of STAT3 protein]
3-nitrobenzanthrone results in increased phosphorylation of MAPK1 protein EREG protein affects the reaction [3-nitrobenzanthrone results in increased phosphorylation of MAPK1 protein]; IL6 protein affects the reaction [3-nitrobenzanthrone results in increased phosphorylation of MAPK1 protein]
3-nitrobenzanthrone results in increased phosphorylation of MAPK3 protein EREG protein affects the reaction [3-nitrobenzanthrone results in increased phosphorylation of MAPK3 protein]; IL6 protein affects the reaction [3-nitrobenzanthrone results in increased phosphorylation of MAPK3 protein]
[NQO1 protein co-treated with NADP co-treated with Acetyl Coenzyme A co-treated with NAT1 protein] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone NAT1 protein results in increased activity of 3-nitrobenzanthrone
[NAT2 protein co-treated with 3-nitrobenzanthrone] results in increased mutagenesis of HPRT1 gene; [NAT2 protein co-treated with Acetyl Coenzyme A] promotes the reaction [[NQO1 protein co-treated with NADP] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone]; [NAT2 protein co-treated with Acetyl Coenzyme A] promotes the reaction [[SULT1A2 protein co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone] NAT2 protein results in increased susceptibility to 3-nitrobenzanthrone NAT2 protein results in increased activity of 3-nitrobenzanthrone
NFE2L2 protein affects the metabolism of 3-nitrobenzanthrone [NFE2L2 protein affects the metabolism of 3-nitrobenzanthrone] which affects the abundance of 3-aminobenzanthrone NFE2L2 protein affects the susceptibility to 3-nitrobenzanthrone
3-nitrobenzanthrone results in increased expression of NQO1 mRNA NQO1 protein results in increased reduction of 3-nitrobenzanthrone [NAT2 protein co-treated with Acetyl Coenzyme A] promotes the reaction [[NQO1 protein co-treated with NADP] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone]; [NQO1 protein co-treated with NADP co-treated with Acetyl Coenzyme A co-treated with NAT1 protein] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone; [NQO1 protein co-treated with NADP co-treated with Phosphoadenosine Phosphosulfate co-treated with SULT1A1 protein] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone; [NQO1 protein co-treated with NADP] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone; [NQO1 protein results in increased reduction of 3-nitrobenzanthrone] which results in increased chemical synthesis of 3-aminobenzanthrone; [NQO1 protein results in increased reduction of 3-nitrobenzanthrone] which results in increased chemical synthesis of N-hydroxy-3-aminobenzanthrone 3-nitrobenzanthrone binds to NQO1 protein NQO1 protein results in increased metabolism of 3-nitrobenzanthrone NQO1 protein results in increased activity of 3-nitrobenzanthrone
[POR protein co-treated with NADP] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone; POR protein results in increased activity of and results in increased reduction of 3-nitrobenzanthrone
3-nitrobenzanthrone results in increased expression of SOX9 mRNA; 3-nitrobenzanthrone results in increased expression of SOX9 protein EREG protein affects the reaction [3-nitrobenzanthrone results in increased expression of SOX9 protein]
3-nitrobenzanthrone results in increased phosphorylation of STAT3 protein EREG protein affects the reaction [3-nitrobenzanthrone results in increased phosphorylation of STAT3 protein]; IL6 protein affects the reaction [3-nitrobenzanthrone results in increased phosphorylation of STAT3 protein]
[NQO1 protein co-treated with NADP co-treated with Phosphoadenosine Phosphosulfate co-treated with SULT1A1 protein] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone; [SULT1A1 protein co-treated with 3-nitrobenzanthrone] results in increased mutagenesis of HPRT1 gene SULT1A1 protein results in increased activity of 3-nitrobenzanthrone SULT1A1 protein results in increased susceptibility to 3-nitrobenzanthrone
3-nitrobenzanthrone results in decreased expression of TP53 mRNA; 3-nitrobenzanthrone results in decreased expression of TP53 protein 3-nitrobenzanthrone results in increased mutagenesis of TP53 gene 3-nitrobenzanthrone results in increased expression of TRP53 protein
EREG protein affects the reaction [3-nitrobenzanthrone results in increased expression of TWIST2 protein] 3-nitrobenzanthrone results in increased expression of TWIST2 mRNA; 3-nitrobenzanthrone results in increased expression of TWIST2 protein
[7-benzylidenenaltrexone binds to and results in decreased activity of OPRM1 protein] which affects the localization of Guanosine 5'-O-(3-Thiotriphosphate); [7-benzylidenenaltrexone binds to and results in decreased activity of OPRM1 protein] which results in increased expression of Cyclic AMP
AKR1B1 protein results in increased reduction of 9,10-phenanthrenequinone AKR1B1 protein results in increased reduction of and affects the activity of 9,10-phenanthrenequinone
AKR1C1 protein results in increased metabolism of 9,10-phenanthrenequinone AKR1C1 protein results in increased reduction of and affects the activity of 9,10-phenanthrenequinone AKR1C1 protein results in increased reduction of 9,10-phenanthrenequinone
AKR1C2 protein results in increased metabolism of 9,10-phenanthrenequinone AKR1C2 protein results in increased reduction of and affects the activity of 9,10-phenanthrenequinone AKR1C2 protein results in increased reduction of 9,10-phenanthrenequinone
AKR1C3 protein results in increased metabolism of 9,10-phenanthrenequinone 9,10-phenanthrenequinone results in increased expression of AKR1C3 protein AKR1C3 protein results in increased reduction of 9,10-phenanthrenequinone [AKR1C3 protein results in increased reduction of 9,10-phenanthrenequinone] which results in increased abundance of Superoxides; AKR1C3 protein results in increased reduction of and affects the activity of 9,10-phenanthrenequinone; Indomethacin analog inhibits the reaction [AKR1C3 protein results in increased metabolism of 9,10-phenanthrenequinone]; Indomethacin inhibits the reaction [AKR1C3 protein results in increased metabolism of 9,10-phenanthrenequinone]; N-(4-chlorobenzoyl)melatonin inhibits the reaction [AKR1C3 protein results in increased metabolism of 9,10-phenanthrenequinone]
AKR7A2 protein results in increased reduction of 9,10-phenanthrenequinone AKR7A2 protein results in increased reduction of and affects the activity of 9,10-phenanthrenequinone 9,10-phenanthrenequinone affects the reduction of AKR7A5 protein
AKR7A3 protein results in increased reduction of 9,10-phenanthrenequinone AKR7A3 protein results in increased reduction of and affects the activity of 9,10-phenanthrenequinone
9,10-phenanthrenequinone results in increased activity of CASP3 protein Acetylcysteine inhibits the reaction [9,10-phenanthrenequinone results in increased activity of CASP3 protein]
9,10-phenanthrenequinone results in increased activity of CASP9 protein Acetylcysteine inhibits the reaction [9,10-phenanthrenequinone results in increased activity of CASP9 protein]
CAT protein inhibits the reaction [[9,10-phenanthrenequinone co-treated with Dithiothreitol] results in decreased activity of and results in increased oxidation of PTPN1 protein] 9,10-phenanthrenequinone results in increased activity of CAT protein
CBR1 protein results in increased metabolism of 9,10-phenanthrenequinone [CBR1 protein co-treated with NADP] results in increased reduction of and affects the activity of 9,10-phenanthrenequinone; [S-Nitrosoglutathione binds to CBR1 protein] promotes the reaction [CBR1 protein results in increased metabolism of 9,10-phenanthrenequinone]
1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [9,10-phenanthrenequinone results in decreased expression of CLDN5 protein]; 2,2'-(hydroxynitrosohydrazono)bis-ethanamine promotes the reaction [9,10-phenanthrenequinone results in decreased expression of CLDN5 protein]; 9,10-phenanthrenequinone results in decreased expression of and affects the localization of CLDN5 protein; Acetylcysteine inhibits the reaction [9,10-phenanthrenequinone results in decreased expression of and affects the localization of CLDN5 protein]; Acetylcysteine inhibits the reaction [9,10-phenanthrenequinone results in decreased expression of CLDN5 mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [9,10-phenanthrenequinone results in decreased expression of and affects the localization of CLDN5 protein]
9,10-phenanthrenequinone inhibits the reaction [[[DCXR protein co-treated with NAD] results in increased reduction of Diacetyl] which results in increased chemical synthesis of Acetoin]; [CBR2 protein co-treated with NADP] results in increased reduction of and affects the activity of 9,10-phenanthrenequinone; [DCXR protein results in increased metabolism of 9,10-phenanthrenequinone] which results in increased chemical synthesis of Hydroxyl Radical
4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline inhibits the reaction [9,10-phenanthrenequinone results in increased phosphorylation of EGFR protein]; catalase-polyethylene glycol inhibits the reaction [9,10-phenanthrenequinone results in increased phosphorylation of EGFR protein]
9,10-phenanthrenequinone results in increased phosphorylation of MAPK1 protein 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline inhibits the reaction [9,10-phenanthrenequinone results in increased phosphorylation of MAPK1 protein]; catalase-polyethylene glycol inhibits the reaction [9,10-phenanthrenequinone results in increased phosphorylation of MAPK1 protein]
4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline inhibits the reaction [9,10-phenanthrenequinone results in increased phosphorylation of MAPK3 protein]; catalase-polyethylene glycol inhibits the reaction [9,10-phenanthrenequinone results in increased phosphorylation of MAPK3 protein]
[NQO1 protein co-treated with NADP] results in increased reduction of and affects the activity of 9,10-phenanthrenequinone; Acetylcysteine inhibits the reaction [NQO1 protein results in increased susceptibility to 9,10-phenanthrenequinone]; NQO1 protein promotes the reaction [Acetylcysteine results in decreased susceptibility to 9,10-phenanthrenequinone] 9,10-phenanthrenequinone results in increased expression of NQO1 protein NQO1 protein results in increased metabolism of 9,10-phenanthrenequinone
[9,10-phenanthrenequinone co-treated with Dithiothreitol] results in decreased activity of and results in increased oxidation of PTPN1 protein; CAT protein inhibits the reaction [[9,10-phenanthrenequinone co-treated with Dithiothreitol] results in decreased activity of and results in increased oxidation of PTPN1 protein]
9-phenanthrol inhibits the reaction [Metribolone binds to AR protein] 9-phenanthrol inhibits the reaction [[6-fluorotestosterone co-treated with Norgestrel] binds to and results in increased activity of AR protein]
CYP1A1 protein results in increased abundance of 9-phenanthrol [CYP1A1 protein results in increased oxidation of phenanthrene] which results in increased abundance of 9-phenanthrol
[CYP1A2 protein results in increased oxidation of phenanthrene] which results in increased abundance of 9-phenanthrol CYP1A2 protein results in increased abundance of 9-phenanthrol
CYP1B1 protein results in increased abundance of 9-phenanthrol [CYP1B1 protein results in increased oxidation of phenanthrene] which results in increased abundance of 9-phenanthrol
[CYP2A13 protein results in increased oxidation of phenanthrene] which results in increased abundance of 9-phenanthrol CYP2A13 protein results in increased abundance of 9-phenanthrol
9-phenanthrol inhibits the reaction [[GCG protein co-treated with Glucose] results in increased secretion of INS1 protein]; 9-phenanthrol inhibits the reaction [Glucose results in increased secretion of INS1 protein] 9-phenanthrol results in increased secretion of INS1 protein
9-phenanthrol inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; 9-phenanthrol inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]
9-phenanthrol inhibits the reaction [Arsenic Trioxide results in increased expression of TRPM4 protein]; 9-phenanthrol inhibits the reaction [Glutamic Acid results in increased activity of TRPM4 protein]; 9-phenanthrol inhibits the reaction [Hydrogen Peroxide results in increased expression of TRPM4 protein] 9-phenanthrol results in decreased activity of TRPM4 protein
dibenzo(aj)anthracene binds to and results in increased activity of AHR protein; dibenzo(aj)anthracene inhibits the reaction [Benzo(a)pyrene binds to AHR protein] dibenzo(aj)anthracene results in increased activity of AHR protein
[naphthalene co-treated with anthracene co-treated with phenanthrene co-treated with pyrene] affects the expression of ACP2 protein phenanthrene affects the expression of ACP2 protein
phenanthrene binds to and results in increased activity of AHR protein phenanthrene binds to AHR protein [acenaphthene co-treated with anthracene co-treated with 1,12-benzoperylene co-treated with 1,2,5,6-dibenzanthracene co-treated with fluorene co-treated with naphthalene co-treated with phenanthrene] results in increased activity of AHR protein; [naphthalene co-treated with phenanthrene co-treated with anthracene co-treated with fluoranthene co-treated with pyrene] results in decreased expression of AHR protein; [phenanthrene co-treated with naphthalene] inhibits the reaction [Benzo(a)pyrene results in increased activity of AHR protein]; [pyrene co-treated with phenanthrene] inhibits the reaction [Benzo(a)pyrene results in increased activity of AHR protein]; AHR protein affects the reaction [[naphthalene co-treated with phenanthrene co-treated with anthracene co-treated with fluoranthene co-treated with pyrene] results in decreased expression of AR protein]; AHR protein affects the reaction [[naphthalene co-treated with phenanthrene co-treated with anthracene co-treated with fluoranthene co-treated with pyrene] results in increased expression of ESR1 protein]; AHRR protein affects the reaction [[naphthalene co-treated with phenanthrene co-treated with anthracene co-treated with fluoranthene co-treated with pyrene] results in decreased expression of AHR protein]; phenanthrene inhibits the reaction [Benzo(a)pyrene results in increased activity of AHR protein] phenanthrene results in increased activity of AHR protein
[naphthalene co-treated with phenanthrene co-treated with anthracene co-treated with fluoranthene co-treated with pyrene] results in decreased expression of AHRR protein; AHRR protein affects the reaction [[naphthalene co-treated with phenanthrene co-treated with anthracene co-treated with fluoranthene co-treated with pyrene] results in decreased expression of AHR protein]; AHRR protein affects the reaction [[naphthalene co-treated with phenanthrene co-treated with anthracene co-treated with fluoranthene co-treated with pyrene] results in decreased expression of CYP1A1 protein]
phenanthrene analog binds to AR protein [naphthalene co-treated with phenanthrene co-treated with anthracene co-treated with fluoranthene co-treated with pyrene] results in decreased expression of AR protein; AHR protein affects the reaction [[naphthalene co-treated with phenanthrene co-treated with anthracene co-treated with fluoranthene co-treated with pyrene] results in decreased expression of AR protein]; phenanthrene inhibits the reaction [[6-fluorotestosterone co-treated with Norgestrel] binds to and results in increased activity of AR protein]; phenanthrene inhibits the reaction [Dihydrotestosterone results in increased activity of AR protein] phenanthrene analog inhibits the reaction [Androgens binds to AR protein]; phenanthrene analog inhibits the reaction [Metribolone binds to AR protein]; phenanthrene inhibits the reaction [Metribolone binds to AR protein]
[naphthalene co-treated with phenanthrene co-treated with anthracene co-treated with fluoranthene co-treated with pyrene] affects the expression of ARNT protein; [naphthalene co-treated with phenanthrene co-treated with anthracene co-treated with fluoranthene co-treated with pyrene] results in decreased expression of ARNT mRNA; [naphthalene co-treated with phenanthrene co-treated with anthracene co-treated with fluoranthene co-treated with pyrene] results in increased expression of ARNT mRNA
[naphthalene co-treated with anthracene co-treated with phenanthrene co-treated with pyrene] affects the expression of BAX protein phenanthrene affects the expression of BAX protein
[naphthalene co-treated with anthracene co-treated with phenanthrene co-treated with pyrene] results in increased expression of CASP3 protein phenanthrene results in increased expression of CASP3 protein
phenanthrene results in increased expression of CAT protein [phenanthrene co-treated with fluorene] results in increased activity of CAT protein phenanthrene results in increased activity of CAT protein
phenanthrene results in decreased expression of CCNA2 protein [naphthalene co-treated with anthracene co-treated with phenanthrene co-treated with pyrene] results in decreased expression of CCNA2 protein
[naphthalene co-treated with anthracene co-treated with phenanthrene co-treated with pyrene] results in increased expression of CCND1 protein phenanthrene results in increased expression of CCND1 protein
[naphthalene co-treated with anthracene co-treated with phenanthrene co-treated with pyrene] results in increased expression of CDK2 protein phenanthrene results in increased expression of CDK2 protein
[naphthalene co-treated with phenanthrene co-treated with anthracene co-treated with fluoranthene co-treated with pyrene] affects the expression of COMT mRNA; [naphthalene co-treated with phenanthrene co-treated with anthracene co-treated with fluoranthene co-treated with pyrene] results in increased expression of and affects the activity of COMT protein
[naphthalene co-treated with anthracene co-treated with phenanthrene co-treated with pyrene] affects the expression of CYP19A1 protein phenanthrene results in increased expression of CYP19A1 protein
[CYP1A1 protein results in increased oxidation of phenanthrene] which results in increased abundance of 9-phenanthrol; [naphthalene co-treated with phenanthrene co-treated with anthracene co-treated with fluoranthene co-treated with pyrene] affects the expression of CYP1A1 mRNA; [naphthalene co-treated with phenanthrene co-treated with anthracene co-treated with fluoranthene co-treated with pyrene] affects the expression of CYP1A1 protein; [naphthalene co-treated with phenanthrene co-treated with anthracene co-treated with fluoranthene co-treated with pyrene] results in decreased expression of CYP1A1 protein; [phenanthrene co-treated with pyrene co-treated with Benzo(a)pyrene co-treated with benzo(k)fluoranthene co-treated with dibenzo(a,l)pyrene co-treated with benzo(b)fluoranthene] results in increased expression of CYP1A1 mRNA; AHRR protein affects the reaction [[naphthalene co-treated with phenanthrene co-treated with anthracene co-treated with fluoranthene co-treated with pyrene] results in decreased expression of CYP1A1 protein]; CYP1A1 protein results in increased metabolism of and results in increased activity of phenanthrene; GSTM1 gene polymorphism promotes the reaction [CYP1A1 gene polymorphism results in increased metabolism of phenanthrene] phenanthrene results in increased expression of CYP1A1 mRNA phenanthrene results in increased expression of CYP1A1 mRNA; phenanthrene results in increased expression of CYP1A1 protein phenanthrene results in increased activity of CYP1A1 protein
phenanthrene results in increased activity of CYP1A2 protein phenanthrene results in increased expression of CYP1A2 mRNA; phenanthrene results in increased expression of CYP1A2 protein CYP1A2 protein results in increased oxidation of phenanthrene [acenaphthylene co-treated with acenaphthene co-treated with dibenzofuran co-treated with fluorene co-treated with phenanthrene co-treated with anthracene] results in increased expression of CYP1A2 mRNA; CYP1A2 protein results in increased metabolism of and results in increased activity of phenanthrene [CYP1A2 protein results in increased oxidation of phenanthrene] which results in increased abundance of 9-phenanthrol; CYP1A2 protein results in increased metabolism of and results in increased activity of phenanthrene
[CYP1B1 protein results in increased oxidation of phenanthrene] which results in increased abundance of 9-phenanthrol; [phenanthrene co-treated with pyrene co-treated with Benzo(a)pyrene co-treated with benzo(k)fluoranthene co-treated with dibenzo(a,l)pyrene co-treated with benzo(b)fluoranthene] results in increased expression of CYP1B1 mRNA; CYP1B1 protein results in increased metabolism of and results in increased activity of phenanthrene; phenanthrene binds to and results in decreased activity of CYP1B1 protein phenanthrene results in increased expression of CYP1B1 mRNA CYP1B1 gene polymorphism results in decreased metabolism of phenanthrene
CYP2A13 protein results in increased oxidation of phenanthrene phenanthrene binds to CYP2A13 protein [CYP2A13 protein results in increased oxidation of phenanthrene] which results in increased abundance of 9-phenanthrol
phenanthrene results in increased expression of CYP2B6 mRNA phenanthrene results in increased expression of CYP2B10 mRNA; phenanthrene results in increased expression of CYP2B10 protein NR1I3 gene mutant form inhibits the reaction [phenanthrene results in increased expression of CYP2B10 mRNA]; NR1I3 gene mutant form inhibits the reaction [phenanthrene results in increased expression of CYP2B10 protein]
[naphthalene co-treated with phenanthrene co-treated with anthracene co-treated with fluoranthene co-treated with pyrene] results in increased expression of ESR1 protein; AHR protein affects the reaction [[naphthalene co-treated with phenanthrene co-treated with anthracene co-treated with fluoranthene co-treated with pyrene] results in increased expression of ESR1 protein]; phenanthrene analog binds to and results in decreased activity of ESR1 protein; phenanthrene binds to and results in increased activity of ESR1 protein
GSTM1 gene polymorphism promotes the reaction [CYP1A1 gene polymorphism results in increased metabolism of phenanthrene] GSTM1 protein affects the metabolism of phenanthrene
phenanthrene affects the expression of IGHE mRNA alternative form phenanthrene results in increased expression of IGHE mRNA; phenanthrene results in increased expression of IGHE protein
phenanthrene results in increased expression of IL6 mRNA; phenanthrene results in increased expression of IL6 protein [fluorene co-treated with phenanthrene] results in increased expression of IL6 mRNA; [fluorene co-treated with phenanthrene] results in increased expression of IL6 protein
[naphthalene co-treated with phenanthrene co-treated with anthracene co-treated with fluoranthene co-treated with pyrene] results in increased expression of NFKB2 protein
phenanthrene results in increased activity of NR1I3 protein NR1I3 gene mutant form inhibits the reaction [phenanthrene results in increased expression of CYP2B10 mRNA]; NR1I3 gene mutant form inhibits the reaction [phenanthrene results in increased expression of CYP2B10 protein]; NR1I3 gene mutant form inhibits the reaction [phenanthrene results in increased expression of CYP3A11 mRNA]; NR1I3 gene mutant form inhibits the reaction [phenanthrene results in increased expression of GSTM3 mRNA]; NR1I3 gene mutant form inhibits the reaction [phenanthrene results in increased expression of SULT2A1 mRNA]; NR1I3 gene mutant form inhibits the reaction [phenanthrene results in increased expression of UGT1A1 mRNA]
phenanthrene affects the reaction [Tretinoin results in decreased expression of POU5F1 protein] phenanthrene results in decreased expression of POU5F1 protein
phenanthrene results in increased expression of SULT2A1 mRNA NR1I3 gene mutant form inhibits the reaction [phenanthrene results in increased expression of SULT2A1 mRNA]
[fluorene co-treated with phenanthrene] results in increased expression of TNF mRNA; [fluorene co-treated with phenanthrene] results in increased expression of TNF protein; TNF protein promotes the reaction [phenanthrene results in increased expression of CXCL8 mRNA] phenanthrene results in increased expression of TNF protein phenanthrene results in increased expression of TNF mRNA; phenanthrene results in increased expression of TNF protein
phenanthrene results in increased expression of UGT1A1 mRNA NR1I3 gene mutant form inhibits the reaction [phenanthrene results in increased expression of UGT1A1 mRNA]
[phenanthrene co-treated with pyrene co-treated with Benzo(a)pyrene co-treated with benzo(k)fluoranthene co-treated with dibenzo(a,l)pyrene co-treated with benzo(b)fluoranthene] results in increased expression of UGT1A6 mRNA
browse the term
